Citations 1
Real-World Impact of Bridging Therapy on Outcomes of Ide-cel for Myeloma in the U.S. Myeloma Immunotherapy Consortium
Afrough, Aimaz , Hashmi, Hamza , Hansen, Doris K. , Peres, Lauren C. , Dima, Danai , Freeman, Ciara L. , Puglianini, Omar Castañeda , Voorhees, Peter M. , Shune, Leyla , Simmons, Gary , Sborov, Douglas W. , Kaur, Gurbakash, Sannareddy, Aishwarya , Ferreri, Christopher J. , Gaballa, Mahmoud , Janakiram, Murali , Midha, Shonali , Wagner, Charlotte B , Patel, Krina K. , Khouri, Jack , Castaneda Puglianini, Omar , Dima, Danai , Wagner, Charlotte , Janakiram, Murali , Hansen, Doris K
No container title available | December 7, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available
Abstract In a retrospective analysis at 11 US medical centers, bridging therapy (BT) impact after receiving idecabtagene vicleucel was assessed in 214 patients. 79% received BT, including 12% Selinexor-containing, 45% alkylator-based, 15% proteasome inhibitor combinations, and 18% immunomodulatory drugs +/- monoclonal antibody combinations (IMiD +/- mAb combos). BT recipients had worse performance status, higher stage disease, ferritin and CRP pre-infusion. The overall response rate to BT was 12%, with no difference among BT subgroups. Safety profiles were similar, but Selinexor had a higher grade ≥2 ICANS incidence. Median progression-free survival (PFS) was 6.7 months in BT vs. 11.5 months in no-BT (p=0.007). Median PFS was longest with IMiD +/- mAb combos (12 months), comparable to no-BT, and significantly longer than other BT subgroups (p=0.01). Alkylator-based BT had inferior PFS compared to IMiD +/- mAb combos (p=0.03). Median overall survival (OS) for the BT was 13.8 months vs. not reached in no-BT (p=0.002). Alkylator-based BT had shorter OS compared to others (11.97 months vs. NR; p=0.001). Stepwise Cox regression showed alkylator-based BT and response